Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi Goes All In For Type 1 Diabetes With Provention Buy

Tzield Was Approved In US In November

Mar 13 2023

• By Kevin Grogan

Sanofi — • Source: Sanofi

Related Content

Provention Plans Two-Phase Launch Of Tzield, Pricing Drug Higher Than Expected

Nov 18 2022

Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Oct 07 2022

Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research

Dec 10 2019

Provention Maps Possible Regulatory Path For Troubled Teplizumab

Sep 15 2021

Related Companies

Provention Bio, Inc.

Sanofi

Amgen, Inc.

Synthorx, Inc.

Translate Bio

Kadmon Holdings, Inc.

Kymab Ltd.

Additional Topics

M & A Business Strategies Commercial Metabolic Disorders BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window